Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT03973671
Recruiting Observational

Prospective Sample Collection for Cancer of Bladder

NCT03973671 · tracked via the Priya Life Science Belgium tracker
Sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Observational
Started
2020-05-29
Last updated
2024-03-28

Condition(s) studied

Urinary Bladder Neoplasms

Study summary

The goal of the Flemish Databank for Urothelial Cancer is to collect clinical and pathological data of patients treated for urothelial cancer (UC).

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * who are aged between 18-90, * who are of male or female sex, * who give their informed consent to collect their clinical and pathological data, * who are planned to undergo TURBT for BC, * who are planned to undergo (salvage) radical cystectomy with or without an extended pelvic lymph node dissection, * who are planned to undergo tumor biopsy (from primary or metastatic tumor), * who are planned to undergo radical nephroureterectomy ± partial cystectomy or segmental ureterectomy, with or without a lymph node dissection, * who are planned to undergo endoscopic tumor biopsy or resection, * from whom metastases will be surgically removed. Exclusion Criteria: * patients who do not give their informed consent to collect their clinical and pathological data, * patients who withdraw their informed consent to use their clinical and pathological data, * patients who refuse the planned treatment, * women who are pregnant or have suspicion of pregnancy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospitals Leuven Leuven Vlaams-Brabant Recruiting

More Universitaire Ziekenhuizen KU Leuven trials in Belgium

Side Effects of a Single Shot Intrathecal Morphine in Clinical Practice, a Retrospective Analysis Active, not recruiting
Glenohumeral Joint Contract Patterns in Osteoarthritic Glenoids Recruiting
Continuous Glucose Monitoring for Women With Gestational Diabetes Recruiting
Flemish Inguinal and Femoral Hernia Prospective Registry Recruiting
The Effect of Odors on Asthma Symptoms Enrolling by invitation

Other trials for the same condition

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder Active, not recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) Recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03973671 on ClinicalTrials.gov ↗ ← All trials in Belgium